Alendronate and raloxifene affect the osteoprotegerin/RANKL system in human osteoblast primary cultures from patients with osteoporosis and osteoarthritis

European Journal of Pharmacology

Volumn 650, Issue 2-3, 2011, Pages 682-687

  Giner, Mercè ^a,b   Rios, Ma José ^b   Montoya, Ma José ^b   Vázquez, Ma Angeles ^b   Miranda, Cristina ^a   Pérez Cano, Ramón ^a,b  

^a HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^b UNIVERSITY OF SEVILLE   (Spain)

Author keywords

Alendronate and raloxifene; Human osteoblast culture; Osteoporosis; Osteoprotegerin RANKL

Indexed keywords

ALENDRONIC ACID; ESTRADIOL; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RALOXIFENE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FEMALE; HIP ARTHROPLASTY; HIP FRACTURE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; KNEE ARTHROPLASTY; MALE; OSTEOARTHRITIS; OSTEOBLAST; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION;

AGED; AGED, 80 AND OVER; ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; CELLS, CULTURED; ESTRADIOL; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOARTHRITIS; OSTEOBLASTS; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPROTEGERIN; RALOXIFENE; RANK LIGAND; RNA, MESSENGER;

EID: 78651097506     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.10.058     Document Type: Article

References (44)

1. A. Bashir, Y.T. Mak, S. Sankaralingam, J. Cheung, N.W. McGowan, A.E. Grigoriadis, I. Fogelman, and G. Hampson Changes in RANKL/osteoprotegerin/RANK gene expression in peripheral mononuclear cells following treatment with estrogen or raloxifene Steroids 70 2005 847 855
2. A. Bitto, B.P. Burnett, F. Polito, H. Marini, R.M. Levy, M.A. Armbruster, L. Minutoli, V. Di Stefano, N. Irrera, S. Antoci, R. Granese, F. Squadrito, and D. Altavilla Effects of genistein aglycone in osteoporotic, ovariectomized rats: a comparison with alendronate, raloxifene and oestradiol Br. J. Pharmacol. 155 2008 896 905
3. J. Cheung, Y.T. Mak, S. Papaioannou, B.A. Evans, I. Fogelman, and G. Hampson Interleukin-6 (IL-6), IL-1, receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin production by human osteoblastic cells: comparison of the effects of 17-beta oestradiol and raloxifene J. Endocrinol. 177 2003 423 433
4. J.E. Compston Sex steroids and bone Physiol. Rev. 81 2001 419 447
5. B. Ettinger, J. San Martin, G. Crans, and I. Pavo Differential effects of teriparatide on bone mineral density after treatment with raloxifene or alendronate J. Bone Miner. Res. 19 2004 745 751
6. D. Fernández-García, M. Muñoz-Torres, P. Mezquita-Raya, M. de la Higuera, G. Alonso, R. Reyes-García, A.S. Ochoa, M.E. Ruiz-Requena, J.D. Luna, and F. Escobar-Jiménez Effects of raloxifene therapy on circulating osteoprotegerin and RANK ligand levels in post-menopausal osteoporosis J. Endocrinol. Invest. 31 2008 416 421
7. J.S. Finkelstein, A. Hayes, J.L. Hunzelman, J.J. Wyland, H. Lee, and R.M. Neer The effects of parathyroid hormone, alendronate, or both in men with steoporosis N Engl J. Med. 349 2003 1216 1226
8. C. García-Moreno, S. Serrano, M. Nacher, M. Farré, A. Díez, M.L. Mariñoso, J. Carbonell, L. Mellibovsky, X. Nogués, J. Ballester, and J. Aubía Effect of alendronate on cultures normal human osteoblasts Bone 22 1998 233 239
9. M. Giner, M.J. Montoya, M.A. Vázquez, M.J. Rios, R. Moruno, M.J. Miranda, and R. Pérez-Cano Modifying RANKL/osteoprotegerin mRNA expression in differentiating and growing human primary osteoblasts Horm. Metab. Res. 40 2008 869 874
10. M. Giner, M.A. Rios, M.A. Montoya, M.A. Vázquez, L. Naji, and R. Pérez-Cano RANKL/osteoprotegerin in primary cultures of osteoblasts from post-menopausal women. Differences between osteoporotic hip fractures and osteoarthritis J. Steroid Biochem. Mol. Biol. 113 2009 46 51
11. N. Giuliani, M. Pedrazzoni, G. Negri, G. Passeri, M. Impicciatore, and G. Girasole Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo Bone 22 1998 455 461
12. S. Greiner, A. Kadow-Romacker, M. Lübberstedt, G. Schmidmaier, and B. Wildemann The effect of zoledronic acid incorporated in a poly (d, l-lactide) implant coating on osteoblasts in vitro J. Biomed. Mater. Res. 80 2007 769 775
13. A.I. Idris, J. Rojas, I.R. Greig, R.J. Van't Hof, and S.H. Ralston Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro Calcif. Tissue Int. 82 2008 191 201
14. G.I. Im, S.A. Qureshi, J. Kenney, H.E. Rubash, and A.S. Shanbhag Osteoblast proliferation and maturation by bisphosphonates Biomaterials 25 2004 4105 4115
15. K.B. Jonsson, A. Frost, O. Nilsson, S. Ljunghall, and O. Ljunggren Three isolation techniques for primary culture of human osteoblast-like cells: a comparison Acta Orthop. Scand. 70 1999 365 373
16. Y.H. Kim, G.S. Kim, and B. Jeong-Hwa Inhibitory action of bisphosphonates on bone resorption does not involve the regulation of RANKL and osteoprotegerin expression Exp. Mol. Med. 34 2002 145 151
17. P.J. Kostenuik Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength Curr. Opin. Pharmacol. 5 2005 618 625
18. S. Kudlacek, B. Schneider, W. Woloszczuk, P. Pietschmann, R. Willvonseder, and Austrian Study Group on Normative Values of Bone Metabolism Serum levels of osteoprotegerin increase with age in a healthy adult population Bone 32 2003 681 686
19. D.L. Lacey, E. Timms, H.L. Tan, M.J. Kelley, C.R. Dunstan, T. Burgess, R. Elliott, A. Colombero, G. Elliott, S. Scully, H. Hsu, J. Sullivan, N. Hawkins, E. Davy, C. Capparelli, A. Eli, Y.X. Qian, S. Kaufman, I. Sarosi, V. Shalhoub, G. Senaldi, J. Guo, J. Delaney, and W.J. Boyle Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation Cell 93 1998 165 176
20. U.A. Liberman, S.R. Weiss, J. Bröll, H.W. Minne, H. Quan, N.H. Bell, J. Rodriguez-Portales, R.W. Downs Jr., J. Dequeker, and M. Favus Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment N Engl J. Med. 333 1995 1437 1443
21. D.M. Lonard, and C.L. Smith Molecular perspectives on selective estrogen receptor modulators (selective estrogen receptor modulators): progress in understanding their tissue-specific agonist and antagonist actions Steroids 67 2002 15 24
22. H. Michael, P.L. Härkönen, L. Kangas, H.K. Väänä nen, and T.A. Hentunen Differential effects of selective oestrogen receptor modulators (selective estrogen receptor modulators) tamoxifen, ospemifene and raloxifene on human osteoclasts in vitro Br. J. Pharmacol. 151 2007 384 395
23. S. Olivier, M. Fillet, M. Malaise, J. Piette, V. Bours, M.P. Merville, and N. Franchimont Sodium nitroprusside-induced osteoblast apoptosis is mediated by long chain ceramide and is decreased by raloxifene Biochem. Pharmacol. 69 2005 891 901
24. B. Pan, A.N. Farrugia, L.B. To, D.M. Findlay, J. Green, K. Lynch, and A.C. Zannettino The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE) J. Bone Miner. Res. 19 2004 147 154
25. S. Panzavolta, P. Torricelli, B. Bracci, M. Fini, and A. Bigi Alendronate and Pamidronate calcium phosphate bone cements: setting properties and in vitro response of osteoblast and osteoclast cells J. Inorg. Biochem. 103 2009 101 106
26. A.M. Parfitt, G.R. Mundy, G.D. Roodman, D.E. Hughes, and B.F. Boyce A new model for the regulation of bone resorption, with particular reference to the effects of bisphosphonates J. Bone Miner. Res. 11 1996 150 159
27. L.I. Plotkin, R.S. Weinstein, A.M. Parfitt, P.K. Roberson, S.C. Manolagas, and T. Bellido Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin J. Clin. Invest. 104 1999 1363 1374
28. A.A. Reszka, J.M. Halasy-Nagy, P.J. Masarachia, and G.A. Rodan Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase J. Biol. Chem. 274 1999 34967 34973
29. B.L. Riggs, and L.C. Hartmann Selective estrogen-receptor modulators mechanisms of action and application to clinical practice N Engl J. Med. 348 2003 618 629
30. B.L. Riggs, and L.J. Melton Bone turnover matters: the raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density J. Bone Miner. Res. 17 2002 11 14
31. R.G. Russell, N.B. Watts, F.H. Ebetino, and M.J. Rogers Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy Osteoporos. Int. 19 2008 733 759
32. M. Sato, W. Grasser, N. Endo, R. Akins, H. Simmons, D.D. Thompson, E. Golub, and G.A. Rodan Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure J. Clin. Invest. 88 1991 2095 2105
33. D. Stefanik, J. Sarin, T. Lam, L. Levin, P.S. Leboy, and S.O. Akintoye Disparate osteogenic response of mandible and iliac crest bone marrow stromal cells to pamidronate Oral Dis. 14 2008 465 471
34. M. Stolina, D. Dwyer, S. Middleton, S. Adamu, M.S. Ominsky, D. Zack, and P.J. Kostenuik Osteoprotegerin prevents osteopenia in arthritic rats via different mechanisms than bisphosphonate therapy J. Bone Miner. Res. 22 2007 S475
35. A. Taranta, M. Brama, A. Teti, V. De luca, R. Scandurra, G. Spera, D. Agnusdei, J.D. Termine, and S. Migliaccio The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro Bone 30 2002 368 376
36. K. Thirunavukkarasu, R.R. Miles, D.L. Halladay, X. Yang, R.J. Galvin, S. Chandrasekhar, T.J. Martin, and J.E. Onyia Stimulation of osteoprotegerin (osteoprotegerin) gene expression by transforming growth factor-beta (TGF-beta). Mapping of the osteoprotegerin promoter region that mediates TGF-beta effects J. Biol. Chem. 276 2001 36241 36250
37. J.H. Tobias, J.W. Chow, and T.J. Chambers 3-Amino-1-hydroxypropylidine-1- bisphosphonate (AHPrBP) suppresses not only the induction of new, but also the persistence of existing bone-forming surfaces in rat cancellous bone Bone 14 1993 619 623
38. L. Tou, N. Quibria, and J.M. Alexander Regulation of human cbfa1 gene transcription in osteoblasts by selective estrogen receptor modulators (selective estrogen receptor modulators) Mol. Cell. Endocrinol. 183 2001 71 79
39. S. Varghese, and E. Canalis Alendronate stimulates collagenase 3 expression in osteoblasts byposttranscriptional mechanisms J. Bone Miner. Res. 15 2000 2345 2351
40. J. Velasco, M.T. Zarrabeitia, J.R. Prieto, J.L. Perez-Castrillón, M.D. Perez-Aguilar, M.I. Perez-Nuñez, C. Sañudo, J. Hernandez-Elena, I. Calvo, F. Ortiz, J. Gonzalez-Macias, and J.A. Riancho Wnt pathway genes in osteoporosis and osteoarthritis: differential expression and genetic association study Osteoporos. Int. 21 2010 109 118
41. V. Viereck, G. Emons, V. Lauck, K.H. Frosch, S. Blaschke, C. Gründker, and L.C. Hofbauer Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts Biochem. Biophys. Res. Commun. 291 2002 680 686
42. V. Viereck, C. Gründker, S. Blaschke, B. Niederkleine, H. Siggelkow, K.H. Frosch, D. Raddatz, G. Emons, and L.C. Hofbauer Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts J. Clin. Endocrinol. Metab. 88 2003 4206 4213
43. F. von Knoch, C. Jaquiery, M. Kowalsky, S. Schaeren, C. Alabre, I. Martin, H.E. Rubash, and A.S. Shanbhag Effects of bisphosphonates on proliferation and osteoblast differentiation of human bone marrow stromal cells Biomaterials 26 2005 6941 6949
44. R.S. Weinstein, P.K. Roberson, and S.C. Manolagas Giant osteoclast formation and long-term oral bisphosphonate therapy N Engl J. Med. 360 2009 53 62